STROKE PROGRAM
Scientific Papers
Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN Jr, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Haley EC, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Haacke EM, Fawaz M, Davis TP, Toga AW, Griffin JH, Zlokovic BV; NeuroNEXT Clinical Trials Network NN104 Investigators (2019) Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann. Neurol. 85 (1), 125-136.
Griffin JH, Zlokovic BV, Mosnier LO (2018) Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132 (2), 159-169.
Sinha RK, Wang Y, Zhao Z, Xu X, Burnier L, Gupta N, Fernández JA, Martin G, Kupriyanov S, Mosnier LO, Zlokovic BV, Griffin JH (2018) PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood 131 (11), 1163-1171.
Lyden P, Weymer S, Coffey C, Cudkowicz M, Berg S, O’Brien S, Fisher M, Haley EC, Khatri P, Saver J, Levine S, Levy H, Rymer M, Wechsler L, Jadhav A, McNeil E, Waddy S, Pryor K (2016) Selecting patients for intra-arterial therapy in the context of a clinical trial for neuroprotection, Stroke 47 (12), 2979-2985.
Griffin JH, Zlokovic BV, Mosnier LO (2015) Activated protein C: biased for translation. Blood 125 (19), 2898-2907.
Guo H, Zhao Z, Yang Q, Wang M, Bell R, Wang S, Chow N, Davis TP, Griffin JH, Goldman SA, Zlokovic BV (2013) An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway. J. Neuroscience 33 (14), 6181-6190. Abstract
Zlokovic BV, Griffin JH (2011) Activated protein C cytoprotective pathways and implications for stroke and neurological disorders. Trends in Neurosciences 34 (4), 1198-2009.
Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV (2009) Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 40 (5), 1864-1869.
Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández J, Chow N, Griffin JH, Zlokovic BV (2009) Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur. J. Neurosci. 29, 1119-1130.
Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103, 1799-1805.
Lyden P, Pryor KE, Coffey CS, Cudkowicz M, Conwit R, Jadhav A, Sawyer RN Jr, Claassen J, Adeoye O, Song S, Hannon P, Rost NS, Hinduja A, Torbey M, Lee JM, Benesch C, Rippee M, Rymer M, Froehler MT, Haley EC, Johnson M, Yankey J, Magee K, Qidwai J, Levy H, Haacke EM, Fawaz M, Davis TP, Toga AW, Griffin JH, Zlokovic BV; NeuroNEXT Clinical Trials Network NN104 Investigators (2019) Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann. Neurol. 85 (1), 125-136.
Griffin JH, Zlokovic BV, Mosnier LO (2018) Activated protein C, protease activated receptor 1, and neuroprotection. Blood 132 (2), 159-169.
Sinha RK, Wang Y, Zhao Z, Xu X, Burnier L, Gupta N, Fernández JA, Martin G, Kupriyanov S, Mosnier LO, Zlokovic BV, Griffin JH (2018) PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood 131 (11), 1163-1171.
Lyden P, Weymer S, Coffey C, Cudkowicz M, Berg S, O’Brien S, Fisher M, Haley EC, Khatri P, Saver J, Levine S, Levy H, Rymer M, Wechsler L, Jadhav A, McNeil E, Waddy S, Pryor K (2016) Selecting patients for intra-arterial therapy in the context of a clinical trial for neuroprotection, Stroke 47 (12), 2979-2985.
Griffin JH, Zlokovic BV, Mosnier LO (2015) Activated protein C: biased for translation. Blood 125 (19), 2898-2907.
Guo H, Zhao Z, Yang Q, Wang M, Bell R, Wang S, Chow N, Davis TP, Griffin JH, Goldman SA, Zlokovic BV (2013) An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR1-Akt Pathway. J. Neuroscience 33 (14), 6181-6190. Abstract
Zlokovic BV, Griffin JH (2011) Activated protein C cytoprotective pathways and implications for stroke and neurological disorders. Trends in Neurosciences 34 (4), 1198-2009.
Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV (2009) Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 40 (5), 1864-1869.
Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández J, Chow N, Griffin JH, Zlokovic BV (2009) Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur. J. Neurosci. 29, 1119-1130.
Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, Zlokovic BV (2001) Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103, 1799-1805.